Literature DB >> 11464008

Pylorus-preserving total pancreatectomy. Early and late results.

M Wagner1, K Z'graggen, C E Vagianos, C A Redaelli, F Holzinger, C Sadowski, C Kulli, H Zimmermann, H U Baer, M W Büchler.   

Abstract

BACKGROUND/AIMS: Preservation of the pylorus is an accepted alternative procedure to the classical Whipple operation for pancreatic head resection but data describing its value for total pancreatectomy are sparse.
METHODS: A prospective analysis of 22 total pancreatectomies performed in a consecutive series of 436 pancreatic resections from 1.11.93 to 1.5.99.
RESULTS: 11 patients underwent total pancreatectomy with preservation of the pylorus. Histopathological examination revealed pancreatic adenocarcinoma in 16 cases and duodenal adenocarcinoma in 1 patient, 5 patients had other types of pancreatic neoplasm. In-hospital mortality was 4.5% (n = 1), cumulative morbidity was 59% and reoperations were performed in 9.1% of cases (n = 2). Median follow-up was 37 months (range 5-66). 62% of patients (n = 13) developed tumor recurrence and 13 patients died during the follow-up period with 10 deaths being cancer related. There was no difference concerning postoperative and follow-up morbidity of survival between patients undergoing pylorus-preserving total pancreatectomy or pancreatectomy with gastrectomy. However, postoperative body weight was increased 3, 6, 9 and 12 months following preservation of the pylorus.
CONCLUSION: Total pancreatectomy with preservation of the pylorus is a feasible type of resection for all types of pancreatic or ampullary tumors, which shows a similar morbidity and long-term survival but improved nutritional recovery compared with standard total pancreatectomy. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11464008     DOI: 10.1159/000050128

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  11 in total

1.  The Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Pancreatic Cancer.

Authors:  Hiroshi Tamagawa; Toru Aoyama; Naoto Yamamoto; Mariko Kamiya; Masaaki Murakawa; Yosuke Atsumi; Masakatsu Numata; Keisuke Kazama; Kentaro Hara; Norio Yukawa; Yasushi Rino; Munetaka Masuda; Soichiro Morinaga
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Total pancreatectomy for pancreatic cancer: indications and operative technique.

Authors:  Yakup Kulu; Bruno M Schmied; Jens Werner; Pietro Muselli; Markus W Büchler; Jan Schmidt
Journal:  HPB (Oxford)       Date:  2009-09       Impact factor: 3.647

3.  A Contemporary Evaluation of the Cause of Death and Long-Term Quality of Life After Total Pancreatectomy.

Authors:  Wenchuan Wu; Rebecca Dodson; Martin A Makary; Matthew J Weiss; Kenzo Hirose; John L Cameron; Nita Ahuja; Timothy M Pawlik; Christopher L Wolfgang; Jin He
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

4.  The Liverpool duodenum-and spleen-preserving near-total pancreatectomy can provide long-term pain relief in patients with end-stage chronic pancreatitis.

Authors:  A R G Sheel; R D Baron; L D Dickerson; P Ghaneh; F Campbell; M G T Raraty; V Yip; C M Halloran; J P Neoptolemos
Journal:  Langenbecks Arch Surg       Date:  2019-11-20       Impact factor: 3.445

5.  Complications of pancreatic surgery.

Authors:  Choon-Kiat Ho; Jörg Kleeff; Helmut Friess; Markus W Büchler
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

6.  Preservation of the pyloric ring confers little benefit in patients undergoing total pancreatectomy.

Authors:  Hideki Takami; Tsutomu Fujii; Mitsuro Kanda; Masaya Suenaga; Kazuo Yamamura; Yasuhiro Kodera
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

7.  Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Dong Do You; Hyung Geun Lee; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

8.  Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy.

Authors:  Toru Aoyama; Keisuke Kazama; Yohei Miyagi; Masaaki Murakawa; Koichiro Yamaoku; Yosuke Atsumi; Manabu Shiozawa; Makoto Ueno; Manabu Morimoto; Takashi Oshima; Norio Yukawa; Takaki Yoshikawa; Yasushi Rino; Munetaka Masuda; Soichiro Morinaga
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

9.  Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine.

Authors:  Toru Aoyama; Yohei Miyagi; Masaaki Murakawa; Koichiro Yamaoku; Yosuke Atsumi; Manabu Shiozawa; Makoto Ueno; Manabu Morimoto; Takashi Oshima; Norio Yukawa; Takaki Yoshikawa; Yasushi Rino; Munetaka Masuda; Soichiro Morinaga
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

Review 10.  Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery?

Authors:  Matthias Glanemann; Baomin Shi; Feng Liang; Xiao-Gang Sun; Marcus Bahra; Dietmar Jacob; Ulf Neumann; Peter Neuhaus
Journal:  World J Surg Oncol       Date:  2008-11-12       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.